Discover the latest reports and memos

Rare Diseases and the Platform Biotech Renaissance
By Claire Burch, Kiran Sheth
The companies best positioned for the next decade will not be those treating orphan drugs as isolated products, but those using rare disease as the commercial and regulatory proving ground for the next generation of biotech platforms.

Ships for America
By Sawsan Haider, Kyle Harrison
In the 1980s, the US came to the conclusion that manufacturing and shipbuilding were commodity processes better suited for lower-cost labor markets in Asia.

The Anti-Aging Therapeutics Boom
By Michael Kim, Claire Burch
Anti-aging medicine is a field that has emerged in academia, the pharmaceutical industry, and the commercial wellness space over the last decade as part of a wider cultural shift in medicine from reactive to preventive care.

Rare Diseases and the Platform Biotech Renaissance
By Claire Burch, Kiran Sheth
The companies best positioned for the next decade will not be those treating orphan drugs as isolated products, but those using rare disease as the commercial and regulatory proving ground for the next generation of biotech platforms.

By Ben Ali Brown

By Ranjani Sundar, Kyle Harrison

By Keerthikan Thirukkumar

By Angela Cen

By Sachin Maini

By Mustafo Mustafokulov

By Catherine Mekhael

By Sophia Ye

By Andrew Taylor

By Estelle Van Praet

By Jack Marks

By Kyle Harrison, Sachin Maini

By Tyler Bordeaux

By Andrew Hui

By Georgi Stanoev

By Rick Gaur

By Mike Kelly, Maxx Yung, Alexander Zou

By Matthew Wong, Sachin Maini

By Colin Yuan, Karina Chen

By Michael Kim
AI / ML
18 Deep Dives · 103 Companies
Fintech
4 Deep Dives · 67 Companies
Cybersecurity
4 Deep Dives · 34 Companies
By navigating this website you agree to our privacy policy.